In a large pharmaceutical company the answer is straightforward: a Head of Clinical Operations runs a function of specialists. In a twenty-person biotech the title means something quite different, and the difference is where hiring decisions go wrong.
What the role owns in a small company
Not a department. A system.
The operating model — how a study actually gets delivered across sponsor, CRO and sites, and who decides what.
Vendor strategy and oversight — which model, which partners, how performance is governed, and the accountability that E6(R3) makes explicitly non-delegable.
Budget and timeline ownership, including the assumptions underneath both and the honesty to revise them.
The operational voice in development decisions — what a protocol will cost to run, whether a timeline is achievable, what a design change does to feasibility.
Inspection readiness as a continuous state rather than a project.
Most of the work is judgment applied to outsourced delivery. Very little of it is managing people directly, which is why hiring against a large-company job description produces a poor fit.
What triggers the hire
Not headcount. The trigger is the point at which operational decisions start carrying development consequences.
Concretely, that tends to be when any of these become true. You are moving into a study whose data will support a financing or a regulatory interaction. You have more than one vendor relationship that needs governing. Your timeline has slipped once and nobody can say precisely why. Or your CEO is spending meaningful time on CRO management, which is the clearest signal of all.
Why the full-time hire is often premature
Two reasons, and neither is cost alone.
The first is workload shape. The demand is intense and episodic — heavy during selection, contracting, start-up and crisis; considerably lighter in steady-state conduct. A full-time senior hire in a two-study company spends real time under-occupied, which is bad for them as well as for you.
The second is seniority mismatch. What a small sponsor needs is senior judgment at low volume. What the budget usually supports is a mid-level hire at full volume. That trade is frequently the wrong way round: the decisions that matter most at this stage — outsourcing model, CRO selection, governance design — are exactly the ones that reward experience.
What fractional leadership actually is
A senior clinical operations leader engaged part-time, typically on a monthly retainer, who carries accountability rather than advising from outside. That distinction matters. A consultant recommends; a fractional executive owns outcomes, holds decision authority, and sits in the forums where decisions get made — including, where appropriate, in front of the board.
It suits the period between "the CEO is managing the CRO" and "we have enough sustained work to justify a full-time VP." For many emerging sponsors that period lasts two to three years.
When to convert to a permanent hire
When the work becomes continuous rather than episodic — multiple concurrent studies, an internal team to build and lead, or a pipeline that requires someone thinking beyond the current program.
A good fractional engagement should make that transition easier rather than harder: the operating model, governance structure and vendor relationships are documented and transferable, and your first permanent hire inherits a functioning system rather than building one from nothing.
The question worth asking first
Not "can we afford a Head of Clinical Operations?" but "who is currently making these decisions, and is that the best use of their time?"
In most emerging biotechs the honest answer is the CEO or the CMO, neither of whom should be spending their week on vendor governance.
When the role is real but the runway is not, fractional executive leadership is the bridge.
